Ticker: RXRX

Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) - Q2 2025 Financial Summary Key Highlights: Net Loss: $171.9 million for Q2 2025, up from $97.5 million in Q2 2024, showing a 76% increase. Operating Revenue: $19.1 million, a 33% increase compared to $14.4 million in Q2 2024. Operating Costs: Incre...